Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Study shows treating vascular anomalies with mitogen‑activated protein kinase inhibitors results in high rates of cutaneous ...
Clinical Trials Arena on MSN
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.
SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors. Blocking this interaction with inhibitors could prevent ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced ...
An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...
SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors. Blocking this interaction with inhibitors could prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback